Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice
- PMID: 17109087
- DOI: 10.1007/s10156-006-0470-y
Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice
Abstract
The neutralization efficacy of bovine colostral antibody against verotoxin (VT) 1 and 2 was investigated. Cows were immunized with VT1 or VT2 fourteen times at 7-day intervals. A colostral antibody exhibiting high titers was obtained from immunized cows. Survival rates were evaluated in mice administered VT1 or VT2, and those infected with Escherichia coli (E. coli) O157:H7 producing VT1 or VT2. Survival rates after VT1 administration were 100% in the single-administration group, 90% in the repeat-administration group, and 78.6% in the control group. Survival rates after VT2 were 75.0% in the single-administration group, and 100% in the repeat-administration group. All mice in the control group died. Colostral antibody and fosfomycin (FOM) in the colostral antibody group and FOM and skim milk in the control group were administered three times per day for 5 days to mice infected with E. coli O157:H7 producing VT1 or VT2. Survival rates after inoculation with E. coli O157:H7 producing VT1 were 80.0% in the colostral antibody group, and 63.6% in the control group. Survival rates after inoculation with E. coli O157:H7 producing VT2 were 83.3% in the colostral antibody group, and 20.0% in the control group. The survival rate in mice without treatment following inoculation with E. coli O157:H7 producing VT2 was 88.2%. The survival rates in mice infected with E. coli O157:H7 strains producing VT1 or VT2 improved after administration of this colostral antibody, which exhibited neutralization efficacy against VT.
Similar articles
-
Comparison of efficacies of bovine immune colostral antibody and each immunoglobulin class against verotoxin 2, flagellum and somatic cells of Escherichia coli O157:H7 in mice.J Microbiol Immunol Infect. 2013 Apr;46(2):73-9. doi: 10.1016/j.jmii.2012.01.002. Epub 2012 May 7. J Microbiol Immunol Infect. 2013. PMID: 22572001
-
Inhibition of verotoxin (VT) 2 absorption into systemic blood from intestine by repeated administration of bovine immune colostral antibody against VT2 in mice.J Microbiol Immunol Infect. 2015 Dec;48(6):583-7. doi: 10.1016/j.jmii.2014.05.013. Epub 2014 Jul 31. J Microbiol Immunol Infect. 2015. PMID: 25087197
-
Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity.Vaccine. 2018 Mar 20;36(13):1728-1735. doi: 10.1016/j.vaccine.2018.02.060. Epub 2018 Feb 23. Vaccine. 2018. PMID: 29483033
-
[Characteristics and molecular biology of verotoxin produced by enterohemorrhagic Escherichia coli].Nihon Rinsho. 1997 Mar;55(3):646-50. Nihon Rinsho. 1997. PMID: 9086774 Review. Japanese.
-
Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents. doi: 10.1128/CMR.17.4.926-941.2004. Clin Microbiol Rev. 2004. PMID: 15489355 Free PMC article. Review.
Cited by
-
Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.Comp Med. 2009 Apr;59(2):163-7. Comp Med. 2009. PMID: 19389308 Free PMC article.
-
Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32435624 Free PMC article. Review.
-
Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.Front Cell Infect Microbiol. 2015 Mar 18;5:24. doi: 10.3389/fcimb.2015.00024. eCollection 2015. Front Cell Infect Microbiol. 2015. PMID: 25853096 Free PMC article. Review.
-
Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle.Vet Res. 2015 Apr 10;46(1):38. doi: 10.1186/s13567-015-0175-2. Vet Res. 2015. PMID: 25889651 Free PMC article.
-
The Role of Escherichia coli Shiga Toxins in STEC Colonization of Cattle.Toxins (Basel). 2020 Sep 21;12(9):607. doi: 10.3390/toxins12090607. Toxins (Basel). 2020. PMID: 32967277 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical